ICHOM

Lung Cancer

Treatment approach covered

Surgery | Radiotherapy | Chemotherapy | Targeted therapy | Immunotherapy | Other



Details

- 1 Includes major surgical complications, major radiation complications, and major systemic therapy complications. Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
- 2 Recorded via the Eastern Cooperative Oncology Group (ECOG) score
- 3 Recommended to track via the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire (EORTC QLQ-LC13)
- 4 Recommended to track via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
- 5 Includes physical, emotional, cognitive, and social function and well-being 6 Includes treatment-related mortality and cause of death

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Lung-Cancer



Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsor



The Working Group



Australia

Robert Stirling | Monash University

Belgium

Jan van Meerbeeck | Antwerp University Hospital

Brazil

Clarissa Baldatto | Clínicas Oncológicas Integradas

Netherlands

Franz Schramel | St. Antonius Hospital

Suresh Senan | VU University Medical Centre Amsterdam

Michel Wouters | Netherlands Cancer Institute

United Kingdom

Matthew Baker

David Baldwin | Nottingham University Hospitals

Diana Borthwick | Edinburgh Cancer Research Centre

Jesme Fox | Roy Castle Lung Cancer Foundation Tom Haswell*

Mick Peake | University Hospital Leicester

United States

Janet Abrahm | Dana-Farber Cancer Institute

David Carbone | Ohio State University Comprehensive Cancer Center

Aileen Chen | Dana-Farber Cancer Institute

Marianna Koczywas | City of Hope National Medical Center

Benjamin Kozower | University of Virginia Health System Kimberley Mak | Dana-Farber Cancer Institute

Reza Mehran | MD Anderson Cancer

*Patient representative